AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04947709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
Study NCT06103006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to >1 set).
Study NCT05072353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEFFICARE
Description: The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound.
Study NCT05414643 — intervention group
Intervention type: OTHER
Intervention: Standard care
Description: No interventions were used, as this is an observational study.
Study NCT05179421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxytocin
Description: 10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
Study NCT05179421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose oxytocin
Description: 10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
Study NCT06496126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerasmart 270 (GC Coop, Tokyo, Japonya)
Description: Hybrid Ceramic Block
Study NCT06496126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverX Flow (GC Coop, Tokyo, Japonya)
Description: Fiber Reinforced Composite Resin
Study NCT06496126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: : G-CEM ONE (GC Coop, Tokyo, Japonya)
Description: Universal Self Adhesive Resin Cement
Study NCT06496126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-Premio Bond (GC Coop, Tokyo, Japonya)
Description: Universal Adhesive
Study NCT06496126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-ænial A'CHORD
Description: Conventional Composite Resin
Study NCT04435275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Assistant first, then Human Coach
Description: Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
Study NCT04435275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Coach first, then Virtual Assistant
Description: instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
Study NCT04889625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A C3
Description: Test Lens
Study NCT04889625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: Control Lens
Study NCT05163652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
Study NCT04760028 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adjusting the depth of anesthesia
Description: After the main procedure, the depth of anesthesia can be adjusted as needed
Study NCT05600855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Study NCT05760781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion
Study NCT04375111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: •Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
Study NCT04375111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracic plane block
Description: •Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
Study NCT06521372 — intervention group
Intervention type: OTHER
Intervention: Magenta AI image analysis tool
Description: MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
Study NCT06530368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic home exercise programs
Description: Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
Study NCT05231460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: narcotic regimen with TAP block
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Study NCT05231460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: narcotic regimen with no TAP block
Description: Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Study NCT05231460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic regimen with TAP block
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Study NCT05231460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic regimen with no TAP block
Description: Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Study NCT05007002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-based therapy
Description: Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
Study NCT05181111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
Study NCT06058039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study NCT06058039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study NCT05320926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Description: Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
Study NCT05320926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
Study NCT05320926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent (Resolute Onyx ®)
Description: zotarolimus-eluting stent (Resolute Onyx ®)
Study NCT05320926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus-eluting stent (Resolute Onyx ®)
Description: zotarolimus-eluting stent (Resolute Onyx ®)
Study NCT05181111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care Monitoring
Study NCT05181111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care Monitoring
Study NCT05236218 — intervention group
Intervention type: OTHER
Intervention: Discrete Choice Experiment (DCE) Patients DCE Questionnaire
Description: Discrete Choice Experiment (DCE) Patients
Study NCT05236218 — intervention group
Intervention type: OTHER
Intervention: Semi-Structured Interview Patients Interview
Description: First version of questionnaire (readability/comprehension check)
Study NCT05225857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
Study NCT05128175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
Study NCT05128175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
Study NCT05410626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prolong-release methylphenidate
Description: This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
Study NCT05410626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolong-release methylphenidate
Description: This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
Study NCT05824806 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP Protocol A
Description: Platelet rich plasma protocol A
Study NCT05824806 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP Protocol B
Description: Platelet rich plasma protocol B
Study NCT05824806 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronic acid
Study NCT05225857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.
Study NCT06282185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: supervised training program for twelve weeks + usual care + advice about exercise
Study NCT05508308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyMate
Description: Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
Study NCT05508308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual oxygen control
Description: Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
Study NCT05791968 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Whole blood standard donation
Description: Effects of a standard whole blood donation on iron stores and insulin sensitivity.
Study NCT05791968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood standard donation
Description: Effects of a standard whole blood donation on iron stores and insulin sensitivity.
Study NCT04853719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: oral anticoagulants plus antiplatelet agent
Study NCT04853719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: oral anticoagulants plus antiplatelet agent
Study NCT04996485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Injection
Description: Pathogenetic therapy with biologic drugs
Study NCT04996485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Injection
Description: Pathogenetic therapy with biologic drugs
Study NCT04996485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Injection
Description: Pathogenetic therapy with biologic drugs
Study NCT04996485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic therapy
Description: Active external agents, Emollients, systemic retinoids if needed
Study NCT05449691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage immediate breast reconstruction
Description: One-stage mesh assisted implant breast reconstruction
Study NCT05449691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-stage immediate breast reconstruction
Description: One-stage mesh assisted implant breast reconstruction
Study NCT05522257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-JK-PSMA-7 PET/CT scan
Description: A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
Study NCT05476172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest Pill
Description: The effect of dienogest on endometriosis pain symptoms.
Study NCT05476172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate
Description: The effect of Norethindrone Acetateon endometriosis pain symptoms.
Study NCT05340036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bimaxillary orthognathic surgery using conventional plates
Description: le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion.
Study NCT05340036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery using patient specific plates
Description: The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws.
Study NCT04923568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: Participants will experience 2 sessions of the EaseVRx device for chronic pain
Study NCT05451563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-S
Description: Wearable device for intercourse
Study NCT04590573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)
Description: 5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
Study NCT04590573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)
Description: 5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.